Drugs / CS1002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04338724 | Dec 2019 → Sep 2020 | neoplasm | CStone Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03523819 | Apr 2018 → Jan 2022 | cancer | CStone Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04338724 ↗ |
| Action | Inhibit | “Anti-CTLA-4” NCT03523819 ↗ |
| Modality | Monoclonal antibody | “Anti-CTLA-4 Monoclonal Antibody CS1002” NCT03523819 ↗ |
| Route | Intravenous | “Participants will receive CS1002 intravenously at specified dose on specified days.” NCT03523819 ↗ |